RE: Re: Jim is back27 Jun 2018 09:16
PP
I too believe something is afoot, however. Given what we have seen before with this share being traded, I would not be surprised if investors are taking a gamble on the possible release of sales figures in the next few weeks by way of the half yearly report.
That said, I'm pretty sure they will not be sufficient to suppress yet another profit warning, which we know although is only a paper exercise, it will still have to some extent a psychological negative effect. What will be interesting is the magnitude of the said profit warning, if sales figures are included. I wonder just how accurate they need to be for a half yearly report...could they even be left out and replaced with just a few comforting or otherwise words since it will probably be a while to pull that sort of thing together...or is it ? If Recordati know exactly how many cans have been manufactured and know who they have been distributed to, is this sufficient enough to use as approximate sales figures, which is certainly a lot simpler ?
As to your comments re the board, I think I am right in writing that you are not alone with these views. As professionals, based on their current track record, they need to go back to school and learn about honesty, how not to mislead and how to do their homework properly before releasing, in some instances to deliberately confuse and mislead shareholders. They need to take an extra subject called investor relations as well as some evening classes in pharmaceutical business studies. Oh and when writing reports don't try and hide information from investors by placing such things as FDA information in the end of year financial report (3 months after the end of year), which deserved its own announcement given all the hype they played with regarding the USA launch. To my mind that was a deliberate attempt to hide from investors some valuable information in a 206 page document, which they know most investors will not read, let alone know its been published and where to find it.